A follow-up extension study of patients who completed the U-LaserPrint-1 clinical trial to evaluate the long-term safety and efficacy of treatment with InvivoLPrint-U.
Sponsor: Phosprint S.A.
Phase: 1
Disease: Muscle-invasive bladder cancer
EU trial number: 2026-527804-26-00
Population: Patients with muscle-invasive bladder cancer who completed the parent U-LaserPrint-1 first-in-human study, including radical cystectomy and orthotopic neobladder reconstruction using the InvivoLPrint-U therapy, and who consent to long-term follow-up.
Register Investigator Interest
Interested in offering this trial to suitable patients?